分子薬理部（矢守隆夫部長）と全薬工業が共同開発した分子標的薬ZSTK474の臨床試験が開始されました。がんの増殖に必要なPI3キナーゼを阻害する本剤は非臨床試験で強い抗がん効果と低毒性を示し、放射線との併用による効果増強が証明されています。 詳細
- Takeuchi, K., Soda, M., Togashi, Y., Suzuki, R., Sakata, S., Hatano, S., Asaka, R., Hamanaka, W., Ninomiya, H., Uehara, H., Lim Choi, Y., Satoh, Y., Okumura, S., Nakagawa, K., Mano, H., Ishikawa, Y.
- RET, ROS1 and ALK fusions in lung cancer.
Nat Med, in press (2012)- Togashi, Y., Soda, M., Sakata, S., Sugawara, E., Hatano, S., Asaka, R., Nakajima, T., Mano, H., Takeuch, K.
- KLC1-ALK: A novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only.
PLoS One, 7, e31323 (2012)- Goyama, S., Takeuchi, K., Kanda, Y., Nannya, Y., Chiba, S., Fukayama, M., Kurokawa, M.
- Post-transplant endothelial disorder after hematopoietic SCT: a blinded autopsy study.
Bone Marrow Tansplant, in press (2011)- Yokoyama, T., Toki, T., Aoki, Y., Kanezaki, R., Park, M., Kanno, Y., Takahara, T., Yamazaki, Y., Ito, E., Hayashi, Y., Nakamura, T.
- Identification of TRIB1 R107L gain-of-function mutation in human acute megakaryocytic leukemia.
Blood, in press (2012)- Sugawara, E., Togashi, Y., Kuroda, N., Sakata, S., Hatano, S., Asaka, R., Yuasa, T., Yonese, J., Kitagawa, M., Mano, H., Ishikawa, Y., Takeuchi, K.
- Identification of anaplastic lymphoma kinase fusions in renal cancer.
Cancer,in press (2012)
(109.2KB)
